Laboratory Detection of Cannabinoids

Dl, King; Pa, Martel; Cm, O'Donnell

doi:10.1016/s0272-2712(18)30736-4

Cited by 9 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The specificity of the UTHC method to various cannabinoids and cannabinoid metabolites is shown in table 2. The single most abundant marijuana metabolite found in urine after smoking or ingestion is 11-nor-Ag-THC-9 carboxylic acid [4]. Therefore, a monoclonal antibody having good reactivity to this metabolite was utilized in the method.…”

Section: Discussionmentioning

confidence: 99%

Development and analytical performance of an automated screening method for cannabinoids on the Dimension clinical chemistry system

Obzansky¹,

Gorman²,

Kramer³

et al. 1997

Journal of Analytical Methods in Chemistry

View full text Add to dashboard Cite

A fully automated, random access method for the determination of cannabinoids (UTHC) was developed for the Dimension AR and XL clinical chemistry systems. The method utilizes Abuscreen ONLINE reagents and a multianalyte liquid calibrator containing 11-nor-Δ9-THC-9-carboxylic acid. Within-run and total reproducibility, determined using NCCLS protocol EP5- T2, was less than 0.6% and 1.6% CV, respectively, at all concentrations. Calibration stability was retained for at least 30 days. An extensive evaluation of non-structurally related drugs and various physiological substances indicated lack of interference in the method. No sample carry-over was observed following a specimen containing 1886 ng/ml 11-nor-Δ9-THC-9-carboxylic acid. A 99.1% agreement (N = 445 samples) was found between an EMIT based method on the aca discrete clinical analyser and the Dimension UTHC method. Dimension clinical chemistry system and aca discrete clinical analyser are registered trademarks of Dade International.

show abstract

Section: Discussionmentioning

confidence: 99%

Development and analytical performance of an automated screening method for cannabinoids on the Dimension clinical chemistry system

Obzansky¹,

Gorman²,

Kramer³

et al. 1997

Journal of Analytical Methods in Chemistry

View full text Add to dashboard Cite

show abstract

“…Tests of THC in the blood are difficult and costly. Urinary assays (Teale et al, 1974;Magliozzi et al, 1983;King et al, 1987;Zwerling et al, 1990) are in use, but the cheaper ones are often inaccurate and even the more expensive and accurate ones are fallible because of laboratory error and possible passive exposure to marihuana smoke.…”

Section: The Hemp Plant and Pharmacokineticsmentioning

confidence: 99%

Cannabis, mind, and mirth

Ames

Castle

1996

Eur. psychiatr.

View full text Add to dashboard Cite

In the context of the discovery of the cerebral ligand for the cannabis receptor, and the elucidation of its genetic sequence, we discuss the psychomimetic properties of Cannabis sativa, and explore the relationship between cannabis intoxication and mood. We suggest that renewed study of acute cannabis encephalopathy would be rewarding not only in deepening our understanding of consciousness in healthy adults, but also in helping us to understand the perceptual world of the child, the elderly, and some of our patients.

show abstract

Clinical Features and Management of Intoxication Due to Hallucinogenic Drugs

Leikin

Krantz

Zell-Kanter

et al. 1989

Med Toxicol Adverse Drug Exp

View full text Add to dashboard Cite

Hallucinogenic drugs are unique in that they produce the desired hallucinogenic effects at what are considered non-toxic doses. The hallucinogenic drugs can be categorised into 4 basic groups: indole alkaloid derivatives, piperidine derivatives, phenylethylamines and the cannabinols. The drugs reviewed include lysergic acid diethylamide (LSD), phencyclidine (PCP), cocaine, amphetamines, opiates, marijuana, psilocybin, mescaline, and 'designer drugs.' Particularly noteworthy is that each hallucinogen produces characteristic behavioural effects which are related to its serotonergic, dopaminergic or adrenergic activity. Cocaine produces simple hallucinations, PCP can produce complex hallucinations analogous to a paranoid psychosis, while LSD produces a combination of hallucinations, pseudohallucinations and illusions. Dose relationships with changes in the quality of the hallucinatory experience have been described with amphetamines and, to some extent, LSD. Flashbacks have been described with LSD and alcohol. Management of the intoxicated patient is dependent on the specific behavioural manifestation elicited by the drug. The principles involve differentiating the patient's symptoms from organic (medical or toxicological) and psychiatric aetiologies and identifying the symptom complex associated with the particular drug. Panic reactions may require treatment with a benzodiazepine or haloperidol. Patients with LSD psychosis may require an antipsychotic. Patients exhibiting prolonged drug-induced psychosis may require a variety of treatments including ECT, lithium and l-5-hydroxytryptophan.

show abstract

Laboratory Detection of Cannabinoids

Cited by 9 publications

References 51 publications

Development and analytical performance of an automated screening method for cannabinoids on the Dimension clinical chemistry system

Development and analytical performance of an automated screening method for cannabinoids on the Dimension clinical chemistry system

Cannabis, mind, and mirth

Clinical Features and Management of Intoxication Due to Hallucinogenic Drugs

Contact Info

Product

Resources

About